UnknownNot Applicable

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

China1,150 participantsStarted 2022-05-01

Plain-language summary

This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1.Established and well documented ITP diagnosis * 2.Patient is treated with, or at enrollment prescribed hetrombopag for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study. * 3.Signed and dated informed consent provided by the patient before any study-related activities are undertaken * 4.Willing and able to comply with protocol requirements Exclusion Criteria: * Enrollment in a concurrent clinical interventional study

What they're measuring

Adverse events

Timeframe: Data will be collected for all routine visits completed during the study period no more than 24 months.

Trial details

NCT IDNCT05333861

SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-01

View on ClinicalTrials.gov More Primary Immune Thrombocytopenia trials